Nuformix PLC
NFX
Company Profile
Business description
Nuformix PLC is a pharmaceutical development company. It operates in pharmaceutical development, targeting unmet medical needs in fibrosis and oncology through drug repurposing. Its pipeline products include NXP001, NXP002, and NXP004. Geographically, the company operates only in the UK.
Contact
C/O Arch Law Limited
8 Bishopsgate
Huckletree Bishopsgate
LondonEC2N 4BQ
GBRT: +44 3332423976
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 September 2027
Employees
3
Stocks News & Analysis
stocks
Meta earnings: Early look at Muse adoption impresses investors
We see the company’s momentum in its core advertising business, as well as adoption of Muse, as early signals that the firm’s AI playbook is working.
stocks
Tesla earnings: Shares fall on slower deliveries growth outlook; Raising valuation
Our increased valuation comes from higher full self-driving adoption assumptions and a lower near- and medium-term capital expenditures forecast.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,905.80 | 11.30 | -0.13% |
| CAC 40 | 7,756.49 | 54.77 | -0.70% |
| DAX 40 | 25,224.72 | 147.03 | -0.58% |
| Dow JONES (US) | 52,867.98 | 11.89 | 0.02% |
| FTSE 100 | 10,696.81 | 28.22 | -0.26% |
| HKSE | 23,106.19 | 171.51 | 0.75% |
| NASDAQ | 26,008.86 | 694.00 | -2.60% |
| Nikkei 225 | 62,693.16 | 214.68 | -0.34% |
| NZX 50 Index | 13,733.93 | 12.91 | -0.09% |
| S&P 500 | 7,663.43 | 93.74 | -1.21% |
| S&P/ASX 200 | 8,795.20 | 2.00 | 0.02% |
| SSE Composite Index | 3,690.48 | 32.45 | 0.89% |